PDCD1 and non-small cell lung carcinoma: Irrespective of these limitations, the available data from this and other cohort studies indicate that benzodiazepine (ab)use by NSCLC patients under PD-1/PD-L1 blockade is associated with reduced PFS, OS, and even immune-related adverse events, in line with general immunosuppressive effects of this class of psychotropic drugs.